• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

    11/6/24 4:06:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRUG alert in real time by email
    SC 13G/A 1 sc13g.htm AMENDMENT NO. 1
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.  1)*
     

     
    Bright Minds Biosciences Inc.
     
     
    (Name of Issuer)
     

     
    Common Shares
     
     
    (Title of Class of Securities)
     

     
    10919W405
     
     
    (CUSIP Number)
     

     
    November 4, 2024
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [x]            Rule 13d-1(b)
    [ ]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    1
    Names of Reporting Persons.
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    1,059,331 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    1,059,331 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,059,331 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    17.26%

    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    1,059,331 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    1,059,331 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,059,331 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    17.26%

    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     


    Item 1.
    (a)
    Name of Issuer

     
    Bright Minds Biosciences Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    19 Vestry Street, New York, NY 10013

    Item 2.
    (a)
    Name of Person Filing
     
     
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Common Shares
     
    (e)
    CUSIP Number
     
    10919W405


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [x]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [x]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)          Amount Beneficially Owned***

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b)          Percent of Class***

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c)          Number of shares as to which such person has: ***

    (i)          sole power to vote or to direct the vote

    (ii)          shared power to vote or to direct the vote

    (iii)          sole power to dispose or to direct the disposition of

    (iv)          shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    *** Shares reported herein for Cormorant Asset Management, LP (“Cormorant”) represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein. Cormorant Global Healthcare GP, LLC (“GP LLC”) serves as the general partner of the Master Fund. Cormorant serves as the investment manager of the Master Fund. Bihua Chen serves as the managing member of GP, LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.
    The percentages reported herein with respect to the Reporting Persons’ holdings are based on (i) information provided by the Issuer to the Reporting Persons that there were 4,524,087 shares of Common Shares of the Issuer outstanding as of October 15, 2024 and (ii) a statement in a press release of of the Issuer, dated November 4, 2024, that the Issuer had issued an additional 1,612,902 Common Shares in a private placement.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Cormorant Global Healthcare Master Fund, LP
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    Exhibits                          Exhibit
    99.1                  Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on October 22, 2024.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    November 6, 2024

     
    CORMORANT ASSET MANAGEMENT, LP

     
    By:
    Cormorant Asset Management GP, LLC,
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    /s/ Bihua Chen
     
    Bihua Chen


    Get the next $DRUG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRUG

    DatePrice TargetRatingAnalyst
    5/13/2025Buy
    TD Cowen
    5/7/2025$80.00Buy
    Chardan Capital Markets
    1/23/2025$93.00Overweight
    Piper Sandler
    1/10/2025Overweight
    Cantor Fitzgerald
    1/10/2025$85.00Buy
    H.C. Wainwright
    11/26/2024$75.00Outperform
    Robert W. Baird
    More analyst ratings

    $DRUG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

      - BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention - NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Compan

      5/13/25 8:30:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

      VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders (KOLs) in epilepsy research, as well as an overview of the Company'

      4/28/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

      – Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company's clinical focus on epilepsy – VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epi

      3/4/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Bright Minds Biosciences

      TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy

      5/13/25 9:38:46 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Bright Minds Biosciences with a new price target

      Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00

      5/7/25 8:37:12 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bright Minds Biosciences with a new price target

      Piper Sandler initiated coverage of Bright Minds Biosciences with a rating of Overweight and set a new price target of $93.00

      1/23/25 7:40:15 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Financials

    Live finance-specific insights

    See more
    • Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

      -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.

      4/19/22 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    SEC Filings

    See more
    • SEC Form 6-K filed by Bright Minds Biosciences Inc.

      6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

      4/28/25 7:05:39 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/8/25 3:14:41 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/7/25 4:07:58 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

      -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an

      1/7/25 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

      -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a

      2/27/23 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Announces Resignation of Board Member

      VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br

      1/9/23 4:05:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Cormorant Asset Management, Lp claimed ownership of 452,409 shares (SEC Form 3)

      3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:07:59 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bright Minds Biosciences Inc.

      SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/12/24 4:15:24 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

      SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/6/24 4:06:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bright Minds Biosciences Inc.

      SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/5/24 3:25:38 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care